Duloxetine (Cymbalta) N-nitroso-duloxetine Cancer Lawsuit Lawyers

Duloxetine (Cymbalta) Recall Lawsuit Investigation: FDA Warns of Potential Cancer-Causing Impurity in Recalled Antidepressant

What Parker Waichman LLP Found

• More than 14,000 bottles of Duloxetine were recalled nationwide.
• The medication may contain excessive levels of N-nitroso-duloxetine, a probable human carcinogen.
• The recall involves Duloxetine 30 mg delayed-release capsules distributed by Breckenridge Pharmaceuticals.
• Duloxetine is commonly prescribed for depression, anxiety, fibromyalgia, and chronic pain.
• Patients may have unknowingly taken the contaminated medication for extended periods.

Millions of Americans rely on antidepressant medications every day to manage serious health conditions that can affect every aspect of their lives. Patients trust that the medications they receive have been properly manufactured, tested, and monitored for safety before reaching pharmacy shelves. When contamination concerns arise involving a widely prescribed medication, those patients deserve immediate answers.

A recent recall involving Duloxetine delayed-release capsules has created concern among patients across the United States after federal regulators announced that certain products may contain elevated levels of a potentially cancer-causing substance.

Breckenridge Pharmaceutical, Inc. voluntarily recalled more than 14,000 bottles of Duloxetine delayed-release capsules because the medication may contain excessive amounts of N-nitroso-duloxetine. According to the FDA, this impurity exceeds acceptable limits established under Current Good Manufacturing Practice requirements.

Duloxetine is the generic version of Cymbalta, a medication prescribed to treat several common medical conditions, including major depressive disorder, generalized anxiety disorder, fibromyalgia, diabetic peripheral neuropathy, and chronic musculoskeletal pain.

Because Duloxetine is often taken daily and sometimes for years, contamination concerns involving potential carcinogens may create anxiety for patients who have relied on the medication for long periods of time.

Although the recall has been classified as a Class II recall, meaning serious adverse health consequences are considered less likely than a Class I recall, the presence of elevated nitrosamine compounds remains an issue regulators take seriously.

Patients who have taken the recalled medication may have questions regarding their exposure, future health risks, and potential legal rights.

Understanding Duloxetine And Why So Many Patients Depend On It

Duloxetine belongs to a class of medications known as serotonin-norepinephrine reuptake inhibitors, commonly called SNRIs.

Doctors prescribe the medication to treat a variety of conditions, including:

• Major depressive disorder
• Generalized anxiety disorder
• Fibromyalgia
• Diabetic nerve pain
• Chronic musculoskeletal pain

Unlike medications taken for short-term illnesses, antidepressants are frequently prescribed for months or years. Some patients remain on these medications indefinitely under physician supervision.

Long-term use is one reason contamination issues involving chronic medications receive heightened attention from regulators. Even small amounts of contaminants may become concerning when patients ingest the medication over extended periods.

Many individuals who take Duloxetine have underlying physical or mental health conditions that already require ongoing medical care. Additional concerns about possible carcinogen exposure can create significant emotional distress.

Patients may feel uncertainty about whether they should stop their medication, whether they were exposed to harmful substances, and whether long-term health monitoring may become necessary.

Individuals should never discontinue antidepressant medications abruptly without consulting their healthcare provider because sudden discontinuation can cause withdrawal symptoms and worsening underlying conditions.

What Is N-Nitroso-Duloxetine?

The contamination at issue involves N-nitroso-duloxetine.

Nitrosamines are a group of chemical compounds that have received significant attention from regulators worldwide over the past several years. Various nitrosamines have been discovered in numerous medications, leading to multiple recalls involving products used by millions of consumers.

Certain nitrosamines are classified as probable human carcinogens.

A probable human carcinogen is a substance that may increase the risk of cancer based on available scientific evidence, including animal studies and laboratory research.

It is important for patients to understand that exposure to a probable carcinogen does not automatically mean they will develop cancer. Cancer risk often depends on numerous factors, including:

• The amount of exposure
• The duration of exposure
• Individual health conditions
• Genetic factors
• Age
• Other environmental exposures

Regulatory agencies establish acceptable daily intake limits intended to minimize long-term cancer risks.

When manufacturers discover that impurities exceed those limits, recalls may be initiated to protect consumers from unnecessary exposure.

Nitrosamine contamination has become one of the most significant pharmaceutical manufacturing concerns in recent years, affecting medications used to treat heartburn, blood pressure disorders, diabetes, and other chronic conditions.

Which Duloxetine Products Are Included In The Recall?

The recall involves specific Duloxetine delayed-release capsule products distributed by Breckenridge Pharmaceutical, Inc.

The affected product information includes:

• Product: Duloxetine Delayed-Release Capsules, USP
• Strength: 30 mg
• Bottle Size: 1,000 capsules
• Quantity Recalled: 14,729 bottles
• National Drug Code: 51991-747-10
• Lot Number: 241180C
• Expiration Date: April 2027
• Manufacturer: Towa Pharmaceutical Europe, S.L., Barcelona, Spain
• Distributor: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, New Jersey

Patients should review their prescription bottles carefully before taking any action. Consumers should also contact their pharmacist or prescribing physician if they have concerns regarding whether their medication is affected.

Many patients may have already completed their prescriptions before learning about the recall, which can create additional concerns about prior exposure.

Why Nitrosamine Contamination Continues To Be A Major Public Health Concern

Nitrosamine contamination has become one of the most significant pharmaceutical safety issues regulators have faced during the last several years.

The issue has affected numerous categories of medications worldwide.

Several factors may contribute to nitrosamine formation during pharmaceutical manufacturing, including:

• Chemical interactions during production
• Raw material contamination
• Storage conditions
• Manufacturing process changes
• Quality control failures
• Packaging issues

Because millions of patients consume prescription medications every day, even isolated manufacturing problems can expose large populations to potential risks.

Regulators have increased scrutiny of pharmaceutical manufacturing facilities worldwide to identify vulnerabilities that may contribute to contamination events.

Patients often assume medications are manufactured under identical conditions regardless of where they originate. In reality, pharmaceutical supply chains frequently involve multiple countries, manufacturing plants, ingredient suppliers, and distribution networks.

This complexity makes ongoing quality control essential.

Potential Health Concerns Associated With Long-Term Exposure

One of the most common questions patients ask after nitrosamine recalls involves whether they are now at risk for cancer.

There is no evidence suggesting every person exposed to N-nitroso-duloxetine will develop cancer. However, regulators act because unnecessary exposure to probable carcinogens should be minimized whenever possible.

Patients who have taken contaminated medications for extended periods may wish to discuss their concerns with healthcare providers.

Physicians may evaluate factors such as:

• Length of medication use
• Dosage history
• Family history of cancer
• Existing medical conditions
• Other risk factors

Some patients experience significant emotional distress after learning they may have unknowingly consumed a contaminated medication.

Mental health impacts should not be underestimated, particularly among individuals already being treated for depression or anxiety disorders.

The uncertainty surrounding possible future health effects can create additional burdens for vulnerable patients.

Product Liability Claims Involving Contaminated Medications

Drug manufacturers have legal responsibilities to ensure medications are reasonably safe before they are distributed to consumers.

When contamination occurs, investigations often examine several issues.

Potential legal allegations may include:

• Manufacturing Defects – Manufacturing defect claims may arise if errors during production introduce dangerous contaminants into medications.
• Failure To Warn – Companies may have obligations to notify regulators, physicians, pharmacies, and consumers when contamination risks become known.
• Negligence – Negligence claims may focus on whether manufacturers maintained adequate quality control procedures, inspections, and testing protocols.
• Breach Of Warranty – Consumers have a reasonable expectation that prescription medications will comply with applicable safety standards and manufacturing regulations.

Each case requires careful investigation into production records, testing data, regulatory communications, and patient exposure histories.

What Consumers Should Do Right Now

Patients should not panic if they discover they possess recalled medication.

Consumers should take the following steps:

• Verify whether their prescription matches the recalled lot number
• Contact their pharmacist
• Contact their prescribing physician
• Do not abruptly discontinue antidepressants without medical supervision
• Document prescription records
• Retain pharmacy receipts when available
• Monitor future FDA announcements

Patients who experience unusual symptoms or ongoing concerns should seek medical advice promptly.

Keeping accurate records may become important if additional information emerges regarding the contamination.

Contact Parker Waichman LLP For A Free Case Review

Patients trust that prescription medications have been manufactured safely and tested properly before being dispensed by pharmacies. Learning that a medication used to treat depression, anxiety, fibromyalgia, or chronic pain may contain a potential carcinogen can create tremendous stress and uncertainty.

Parker Waichman LLP is investigating potential claims involving recalled Duloxetine products contaminated with excessive levels of N-nitroso-duloxetine. If you or a loved one took recalled Duloxetine and later developed serious health complications or have concerns regarding long-term exposure, you may have legal rights.

Parker Waichman LLP represents injured consumers nationwide in pharmaceutical injury and product liability litigation.

Call 1-800-YOUR-LAWYER (1-800-968-7529) today for a free consultation. Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.

There are no fees unless compensation is recovered.